Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.30 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL612270 | 0.75 | PARP1 (0.33) | PARP1DYRK1ADYRK2DYRK1B | |
| SCHEMBL4138614 | 0.74 | NPSR1 (0.42) | PARP1LMNASMN1; SMN2 | |
| SCHEMBL30637352 | 0.74 | NPSR1 (0.42) | PARP1LMNASMN1; SMN2 | |
| SCHEMBL1750195 | 0.74 | PARP1 (0.38) | PARP1LMNASMN1; SMN2DYRK1ADYRK2 | |
| SCHEMBL1490042 | 0.72 | MTOR (0.37) | PARP1LMNASMN1; SMN2DYRK1ADYRK2 | |
| SCHEMBL20606050 | 0.72 | LMNA (0.39) | PARP1LMNASMN1; SMN2DYRK1ADYRK2 | |
| SCHEMBL758549 | 0.72 | TP53 (0.37) | PARP1LMNASMN1; SMN2DYRK1ADYRK2 | |
| SCHEMBL22471636 | 0.72 | PARP1 (0.37) | PARP1LMNASMN1; SMN2DYRK1ADYRK2 | |
| SCHEMBL13074743 | 0.72 | PARP1 (0.37) | PARP1LMNASMN1; SMN2DYRK1ADYRK2 | |
| SCHEMBL3929459 | 0.72 | PARP1 (0.37) | PARP1LMNASMN1; SMN2DYRK1ADYRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12138265-B2 | Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2024-11-12 | — | — | US | disclosed |
| US-20230233562-A1 | HETEROARYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-07-27 | — | — | US | disclosed |
| EP-3749666-A1 | HETEROARYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2020-12-16 | — | — | EP | disclosed |
| US-20200383984-A1 | HETEROARYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2020-12-10 | — | — | US | disclosed |
| CN-111971280-A | Heteroaryl compounds, pharmaceutical compositions thereof and therapeutic uses thereof | 耶路撒冷希伯来大学伊萨姆研究发展公司 | 2020-11-20 | — | — | CN | disclosed |
| WO-2020192302-A1 | PYRIMIDINE-CONTAINING TRI-SUBSTITUTED IMIDAZOLE COMPOUND AND APPLICATION THEREOF | 广州必贝特医药技术有限公司 | 2020-10-01 | — | — | WO | disclosed |
| WO-2019155468-A1 | HETEROARYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2019-08-15 | — | — | WO | disclosed |
| US-7589095-B2 | 4-phenyl-pyrimidine-2-carbonitrile derivatives | N.V. ORGANON (NL) | 2009-09-15 | — | — | US | disclosed |
| EP-1758870-B1 | 4-PHENYL-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | ORGANON NV (NL) | 2008-08-13 | — | — | EP | disclosed |
| US-20080090813-A1 | 4-Phenyl-Pyrimidine-2-Carbonitrile Derivatives | Cai, Jiaqiang | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200383984-A1 | HETEROARYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE | CDK9, IRAK1, CSNK1A1 | PARP1 937/4885LMNA 1008/4885SMN1; SMN2 2506/4885 |
| US-12138265-B2 | Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use | CDK9, IRAK1, CSNK1A1 | PARP1 890/4885LMNA 981/4885SMN1; SMN2 2432/4885 |
| US-20230233562-A1 | HETEROARYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE | CDK9, IRAK1, CSNK1A1 | PARP1 890/4885LMNA 981/4885SMN1; SMN2 2432/4885 |
| US-20080090813-A1 | 4-Phenyl-Pyrimidine-2-Carbonitrile Derivatives | P2RY4, P2RX4, P2RY1 | PARP1 220/4885LMNA 3795/4885SMN1; SMN2 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.